Arbutus Biopharma Corporation
ABUS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $529 | $10,739 | $1,764 | $1,574 |
| % Growth | -95.1% | 508.8% | 12.1% | – |
| Cost of Goods Sold | $11 | $0 | $8,959 | $8,810 |
| Gross Profit | $518 | $10,739 | -$7,195 | -$7,236 |
| % Margin | 97.9% | 100% | -407.9% | -459.7% |
| R&D Expenses | $5,778 | $5,498 | $8,959 | $8,810 |
| G&A Expenses | $3,044 | $3,328 | $5,832 | $8,432 |
| SG&A Expenses | $3,033 | $3,328 | $5,832 | $8,432 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $425 | $12,672 | -$10,545 |
| Operating Expenses | $8,811 | $9,251 | $27,463 | $6,697 |
| Operating Income | -$8,293 | $1,488 | -$34,658 | -$13,933 |
| % Margin | -1,567.7% | 13.9% | -1,964.7% | -885.2% |
| Other Income/Exp. Net | $551 | $1,035 | $10,132 | $1,401 |
| Pre-Tax Income | -$7,742 | $2,523 | -$24,526 | -$12,532 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,742 | $2,523 | -$24,526 | -$12,532 |
| % Margin | -1,463.5% | 23.5% | -1,390.4% | -796.2% |
| EPS | -0.04 | 0.013 | -0.13 | -0.068 |
| % Growth | -403% | 110.2% | -92.6% | – |
| EPS Diluted | -0.04 | 0.013 | -0.13 | -0.068 |
| Weighted Avg Shares Out | 191,779 | 191,551 | 190,707 | 185,609 |
| Weighted Avg Shares Out Dil | 191,779 | 192,400 | 190,707 | 189,963 |
| Supplemental Information | – | – | – | – |
| Interest Income | $952 | $1,042 | $1,197 | $1,464 |
| Interest Expense | $23 | $28 | $28 | $30 |
| Depreciation & Amortization | $11 | $11 | $333 | $333 |
| EBITDA | -$7,708 | $2,562 | -$24,165 | -$15,335 |
| % Margin | -1,457.1% | 23.9% | -1,369.9% | -974.3% |